Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.
Hassi Roman M, Mate K, De Pablos-Rodriguez P, Horcajada ÁZ, Cascales AG, Bonet ÁS, Vilaseca A, Vázquez-Martul Pazos D, Espinós EL, Rodríguez JM, de la Morena Gallego JM, Alemán JR, Rivas JG, Formisano L, Juan Fita MJ, Planells MC, Esteban MD, Márquez MP, Sanz MG, Expósito NG, Picola N, Vives PS, Sutil RS, Climent Durán MA, Backhaus MR.
Hassi Roman M, et al. Among authors: mate k.
Eur Urol Open Sci. 2024 Oct 17;70:58-63. doi: 10.1016/j.euros.2024.10.001. eCollection 2024 Dec.
Eur Urol Open Sci. 2024.
PMID: 39474116
Free PMC article.